



GSK is a global pharmaceutical company based in the UK, but with R&D facilities in both the UK and the US. The participant GSK departments in the project are Preclinical Development and Medical Genetics. GSK is a key participant in, and has taken the lead role on a number of safety biomarker initiatives (through C-Path: PSTC, ABPI and ILSI-HESI). GSK will bring this collaborative experience to the project. GSK has experience in collecting, analysing and retaining vast clinical sample sets for the purposes of qualification of putative preclinical safety biomarkers, and discovery of potential biomarkers from across integrated data sources (pharmacogenomics, transcriptomics and metabolomics).

www.gsk.com